For instance, T. cruzi engineered to express NY-ESO-1 antigen, a highly immunogenic cancer-testis antigen elicited strong humoral and CD8 + T-cell responses in mice challenged with NY-ESO-1 + melanoma cells, achieving complete tumor rejection [91]. Here, CD8A is linked to melanoma.